Lowercase letters, wide effects: amwpeptides
GH. IGF-1. DAC. A few letters can make a peptide sound tidy. The blood sample is a busier place.
A serum protein study
My favorite CJC-1295 complication comes from a paper that looked beyond the expected hormone rise. In 11 healthy young adult men, several serum proteins changed after CJC-1295: apolipoprotein A1 and a form of transthyretin decreased, while an albumin fragment and immunoglobulin-related species increased. The immunoglobulin/albumin-fragment signal tracked IGF-1.
That is an exploratory biomarker finding. A biomarker is a measurable sign of a biological response; here, the authors were looking for signs of stimulation. The study establishes neither a health benefit nor a clinical injury from those protein changes. Still, I think its untidy result deserves more space than a neat arrow beside IGF-1. A hormone signal can have company.
GH and IGF-1
Growth hormone, or GH, prompts the liver to produce insulin-like growth factor-1, usually shortened to IGF-1. Sermorelin, CJC-1295 and tesamorelin all stimulate the pituitary through the growth hormone-releasing hormone receptor. The same review describes a much broader field of GHRH biology than the familiar promise of more growth hormone.
A hormone rise gives an incomplete description of benefit. Higher IGF-1 describes a response. Sleep, strength, cognition and fat distribution each require their own observations. The serum protein study makes that problem tangible: even the contents of a blood sample refuse to fit into a single headline.
Measurements across the three compounds
With sermorelin in children with growth hormone deficiency, the outcome was growth in height. The early CJC-1295 trials in healthy adults followed GH and IGF-1 over time. A tesamorelin trial in adults with HIV and abdominal fat accumulation measured visceral fat and liver fat. Those are different experiments with different destinations.
I give the tesamorelin results considerable weight within that HIV population. I doubt that CJC-1295 or sermorelin can inherit those benefits merely by stimulating the same receptor. The CJC-1295 vs sermorelin comparison puts the two most frequently confused names next to their actual measurements; the tesamorelin studies follow the fat findings into their clinical setting.
Safety and approval
The regulatory histories differ too. Sermorelin had a pediatric approval before commercial withdrawal and is now compounded. CJC-1295 has never been approved for human use. Tesamorelin has a specific FDA-approved HIV-associated lipodystrophy indication, described in the NIH drug-safety monograph. For any of the three, a compounded preparation has no FDA approval.
Long-term adult wellness claims still outrun the evidence. The clinical caution about secretagogues and aging remains a useful challenge to that enthusiasm. My question follows the entire response through time: the intended change, the collateral changes and the outcomes a person actually notices.
Sermorelin
Height in children, hormone responses in older men, and adult claims that travel between them.
The growth record →CJC-1295
Albumin binding makes stimulation persist. The serum protein findings widen the question.
The blood sample →Tesamorelin
Measured visceral and liver fat changes in HIV trials, with a precise approval boundary.
The clinical trials →